Autoimmune Hemolytic Anemia in a Pediatric Patient With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

To the Editors:

Multiple clinical manifestations have been described in relation with coronavirus disease 2019 (COVID-19). However, no previously reported cases of autoimmune hemolytic anemia (AIHA) associated to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in children so far. We report a case of severe AIHA in a 13-year-old female with SARS-CoV-2 infection.

The patient was admitted to our hospital because of a 7-day period of fever (37.5°C), asthenia, headache, and a syncope episode without loss of consciousness. She denied respiratory or gastrointestinal symptoms. At admission, she had tachycardia with a heart rate of 114 beats per minute, and normal blood pressure. She also had hypotension with a systolic blood pressure of 80 mmHg, and a diastolic blood pressure of 50 mmHg. Laboratory examination showed a decreased hemoglobin (6.3 g/dL), hematocrit (17.8%), mean corpuscular volume (90.4 fl), mean corpuscular hemoglobin (32 pg), and haptoglobin (<7.38 mg/dL) were normal. Direct Coombs test was performed with a positive result (positive, to SARS-CoV-2). RBCs showed a moderate reticulocytosis (301,600 mm³). Increased lactate dehydrogenase (458 U/L) and hyperbilirubinemia (1.9 mg/dL) were found. Platelet and leukocytes counts, serum ions, and transaminases were normal.

Coagulation and D-dimer did not alter; C-reactive protein (2 mg/L) and ferritin (148.6 mg/dL) were normal. Direct Coombs test was performed with a positive result (positive immunoglobulin G4 [IgG4] and negative C3d). Normal level of glucose-6-phosphate dehydrogenase was found. Platelets and leukocytes counts, serum ions, and transaminases were normal.

Due to the pandemic situation, the reverse transcription-polymerase chain reaction test was performed with a positive result, with negative virus-specific immunoglobulin M and negative virus-specific IgG. Six days later, a new reverse transcription-polymerase chain reaction test was performed, with the negative result but positive virus-specific IgG. Other viral infections were ruled out. Antinuclear, antitopoisomerase nuclear antigens, and anticitrullinated protein antibodies were negative. Chest radiograph showed no alterations.

AIHA was diagnosed and treatment with methylprednisolone pulses (250 mg/daily) was given for the first 72 hours. Afterward, the maintenance dose with prednisolone 1 mg/kg daily was administered. Hemolysis reduced and 14 days later, the hemoglobin value increased to 10.6 g/dL and without the need for blood transfusions.

Recently, 2 studies reported some cases of AIHA associated with COVID-19 in adults.1,2 The median age of adult cases reported by Lazarian et al2 was 62 years and all of them presented risk factors for developing a severe form of COVID-19. All cases started after the beginning of symptoms of SARS-CoV-2 infection. In contrast, our patient did not have any known risk factor for severe SARS-CoV-2 infection, did not suffer any respiratory symptoms and anemia was the only clinical manifestation associated with SARS-CoV-2 infection.

The etiology of AIHA in pediatric population is mostly associated with viral and bacterial infections.3 However, in teenagers and young adults, there is an increased association with underlying systemic illness, most commonly immunodeficiencies and autoimmune disorders.

Our results, after ruling out immunodeficiency, autoimmune disorder, or other viral infection, suggest that SARS-CoV-2 could have triggered AIHA, being the first pediatric case reported so far.

In conclusion, this case suggests that SARS-CoV-2 can trigger AIHA in predisposed children. In the current epidemiologic situation, upon the finding of severe hemolytic anemia without any apparent cause in a previously healthy child, SARS-CoV-2 infection should be ruled out.

Pilar Vega Hernández, MD Vaiskybele Borges Rivas, MD Estefanía Ortega Sánchez, MD Araceli Marqués Cabrero, MD Laura Remedios Mateo, MD Patricia Silvera Roig, MD Aranzazu Infante Quintanar, MD Rafael Diaz-Delgado Peñas, MD Verónica Sánchez Escudero, MD Maria Luz García-García, PhD Pediatrics Department Severo Ochoa University Hospital Leganés, Madrid, Spain

REFERENCES


Open

Is Nasopharyngeal Swab Comparable With Nasopharyngeal Aspirate to Detect SARS-CoV-2 in Children?

To the Editors:

In December 2019 appeared in China a novel coronavirus, designated as SARS-CoV-2, responsible for a pandemic respiratory disease, known as coronavirus disease, with the Italian outbreak from February 2020. Children appear to have milder symptoms and less severe disease.1 The tests currently used for the direct identification of SARS-CoV-2 include specimens taken from the upper and the lower respiratory tract.2,3 Since the use of nasopharyngeal aspirate (NPA) seemed to be better than nasopharyngeal swab (NS) to identify respiratory virus in pediatrics, we decided to compare these methods in detecting SARS-CoV-2 in children.4

Children hospitalized in our pediatric department underwent NS (Copan-503CS01 nasopharyngeal flocked swab) and NPA (Medicoplast mucus extractor 440-ch08), performed from both nostrils, on admission and after 24 hours. SARS-CoV-2 RNA was extracted from the paired samples through nucleic acid amplification, using the RT-PCR.

From March 13 to May 22, 300 paired specimens (NS/NPA) collected from 136 patients (134 hospitalized and 2 outpatients) were tested for SARS-CoV-2.

For clinical aims, we considered positive, to SARS-CoV-2 every patient whose NPA or NS NPA/NS resulted positive or weak positive.

Out of the 134 patients hospitalized, 18 children tested positive (prevalence 13.4%, 95% confidence interval (CI)

The authors have no funding or conflicts of interest to disclose.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 0891-3668/20/3909-e288
DOI: 10.1097/INF.0000000000002824
TABLE 1. NS and NPA Results

<table>
<thead>
<tr>
<th></th>
<th>NPA negative</th>
<th>95% CI</th>
<th>NPA positive</th>
<th>95% CI</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>All children's</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specimens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS negative</td>
<td>251 (97.7%)</td>
<td>94.9%–98.9%</td>
<td>18 (41.9%)</td>
<td>28.2%–56.9%</td>
<td>269 (89.7%)</td>
</tr>
<tr>
<td>NS positive</td>
<td>6 (2.3%)</td>
<td>1.1%–5.1%</td>
<td>25 (58.1%)</td>
<td>43.1%–71.8%</td>
<td>31 (10.3%)</td>
</tr>
<tr>
<td>Total</td>
<td>257 (100.0%)</td>
<td></td>
<td>43 (100.0%)</td>
<td></td>
<td>300 (100.0%)</td>
</tr>
<tr>
<td>Children &lt; 6 years of age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS negative</td>
<td>134 (97.8%)</td>
<td>90.4%–99.3%</td>
<td>4 (33.3%)</td>
<td>12.5%–63.6%</td>
<td>138 (92.8%)</td>
</tr>
<tr>
<td>NS positive</td>
<td>3 (2.2%)</td>
<td>0.7%–6.6%</td>
<td>8 (66.7%)</td>
<td>36.4%–87.5%</td>
<td>11 (7.2%)</td>
</tr>
<tr>
<td>Total</td>
<td>137 (100.0%)</td>
<td></td>
<td>12 (100.0%)</td>
<td></td>
<td>149 (100.0%)</td>
</tr>
<tr>
<td>Children ≥ 6 years of age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS negative</td>
<td>117 (97.5%)</td>
<td>92.5%–99.2%</td>
<td>14 (45.2%)</td>
<td>28.9%–62.6%</td>
<td>131 (86.8%)</td>
</tr>
<tr>
<td>NS positive</td>
<td>3 (2.5%)</td>
<td>0.8%–7.5%</td>
<td>17 (54.8%)</td>
<td>37.4%–71.1%</td>
<td>20 (13.2%)</td>
</tr>
<tr>
<td>Total</td>
<td>120 (100.0%)</td>
<td></td>
<td>31 (100.0%)</td>
<td></td>
<td>151 (100.0%)</td>
</tr>
</tbody>
</table>

8.2%–20.4%); among the latter, 13 of them and 2 outpatient children were followed collecting their paired specimens until both resulted negative 24 hours apart.

Of the 300 paired specimens evaluated, 276 were concordant, 24 were discordant, so the naïve concordance was 92.0% (95% CI 88.3%–94.6%) with Cohen’s kappa (K) 0.63. Among the paired specimens whose NPA resulted positive, 41.9% (95% CI 28.2%–56.9%) had NS negative; while among the paired specimens whose NS resulted negative, 2.3% (95% CI 1.1%–5.1%) had NS positive.

Considering NS as the gold standard for detection of SARS-CoV-2, we calculated sensitivities and specificities of NS. The overall sensitivity of NS was 58.1% (95% CI 43.1%–71.8%) and the specificity was 97.7% (95% CI 94.9%–98.9%). Since the different practice in specimen collection, we divided our cohort according to the children’s age (<6 or ≥6 years, Table 1). Among children under 6 years, the concordance was K = 0.67. Regarding children of 6 years or older, the concordance was K = 0.60.

The NS has, in any case, a low sensitivity in detecting SARS-CoV-2 in children when referred to NPA. Our results, the first we know are available, suggest to prefer the collection of NPA whenever possible for the detection of SARS-CoV-2 in children.

ACKNOWLEDGMENTS

TestingPediatricCOVID-19(TPC-19) study group: Paola Marchisio, MD, Silvana Castaldi, MD, Elia Biganzoli, PhD, Patrizia Boracchi, Samantha Bosti, MD, Giovanna Lunghi, MD, Ferruccio Ceriotti, MD, Giuseppe Bertolozzi, MD, Carlo Agostoni, MD, and Andrea Gori, MD

Ester Luconi, MSc
Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milan, Italy
On behalf of Testing Pediatric COVID-19 (TPC-19)

REFERENCES


Clinical Severity of Gastroenteritis in Children Hospitalized With Rotavirus Infection Before and Post Introduction of a National Rotavirus Vaccination Program in Australia

There have been dramatic reductions in emergency department visits and hospital admissions for gastroenteritis in young children following the introduction of rotavirus vaccination, into the National Immunisation (NIP) program in Australia since May 1, 2007.1,2 However, the diversity of rotavirus strains causing disease in Australia has increased following introduction of the rotavirus vaccine program, with postvaccination era predominant strains varying between states implementing RV1 (Rotarix; GlaxoSmithKline Biologicals, Belgium) versus RV5 (Rotarix; Merck & Co. Inc., Whitehouse Station, New Jersey 08889, USA) vaccine, illustrating the need for continued surveillance and monitoring of rotavirus disease and severity.3

To explore the impact of vaccination on clinical severity of rotavirus disease, we reviewed all laboratory confirmed rotavirus admissions to the Women’s and Children’s Hospital, a tertiary pediatrics hospital in South Australia, for children under 5 years of age during 2 time periods (prevaccine introduction: May 1, 2005–April 3, 2007 and postvaccine introduction May 1, 2009–April 30, 2013). Medical records were reviewed to determine the severity of rotavirus infections assessed using the Vesikari Clinical Severity Scale, VCSS1 and vaccination history was ascertained from the Australian Immunisation Register (AIR). Nosocomial infections were excluded, and readmissions to hospital within 72 hours were considered 1 event. Research ethics approval was obtained from the Women’s and Children’s Health Network Human Research Ethics Committee (REC322A).

A total of 233 pre- and 79 postvaccination period rotavirus admissions were identified and assessed. The proportion of children supported in part by a research grant from the Investigator Initiated Studies Program of Merck (IISP#38070). The opinions expressed in this article are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. M.C., H.M. and S.M. are investigators on clinical vaccine trials sponsored by Industry. Their institution receives funding from Industry (GSK, Pfizer, Sanofi, Novavax) for investigator led research. None of the authors receive any personal payments from Industry. Y.L. has no conflicts to declare.

M.C. and H.M. codesigned the study. M.C. performed statistical analysis and drafted the manuscript. H.M. contributed to analysis plan, review and editing of the manuscript. Y.L. contributed to case note review and analysis plan and review/editing of the manuscript. S.M. contributed to interpretation and review and editing of the manuscript. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship. We further confirm that the order of authors listed in the manuscript has been approved by all.

Address for correspondence: Michelle Clarke, BAppSc (Med Lab), GDSTC, MPPH, Senior Medical Scientist, Vaccinology and Immunology Research Trials UnitWomen’s and Children’s Hospital, 72 King William Rd, North Adelaide, South Australia 5006, Australia. E-mail: michelle.clarke@adelaide.edu.au.

Key Words: rotavirus, severity, children, gastroenteritis, hospitalization

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

© 2020 Wolters Kluwer Health, Inc. All rights reserved.